FDA grants fast track designation to DKN-01 for two gastrointestinal cancers

The FDA granted fast track designation to DKN-01 for the treatment of certain patients with gastric cancer or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.The designation applies to use of DKN-01 (Leap Therapeutics) by patients whose tumors express high Dickkopf-1 protein (DKK1) and whose disease progressed during or after fluoropyrimidine- and platinum-containing chemotherapy and — if appropriate — HER-2 targeted therapy.DKN-01 is a humanized monoclonal antibody that binds to and blocks activity of the DKK1 protein, a modulator ofRead More

Share on facebook
Share on twitter
Share on linkedin